Dyax & Cubist Sign Development and Commercialization Agreement for DX-88 Surgical Indications
04.24.08 –
Cubist Repurchases $50 Million of Its 2.25% Convertible Subordinated Notes Due June 15, 2013
02.07.08 –
Reduces Cubist's Dilutive Potential Shares Outstanding by More Than 1.6 Million Shares
stories:
Cubist Pharmaceuticals (NASDAQ: CBST) is a biopharmaceutical company focused on developing and commercializing antiinfective therapies for the acute care environment. The men and women of Cubist, some who are pictured on our web site, are part of an organization that is determined to take on the challenges associated with providing new antimicrobial therapies to combat the "super bugs". The information on these pages will tell you more about our success to date and our plans for the future.
| Last | 18.51 |
|---|---|
| Change |  0.00 |
| % Change | 0.00% |
| Bid | 18.30 |
| Bid Size | 100 |
| Ask | 19.00 |
Quotes Delayed At Least 20 Minutes
Cubist Investor Relations »
Next Earnings Call Information »
